Updated
SanofiSNY · Healthcare
$47.04+0.28%
Market cap$112.7B
IndustryDrug Manufacturers - General
Sanofi (SNY) Revenue breakdown
By segment, Biopharma is the largest at 88% of fiscal 2023 revenue, growing 7% a year over 2 years.
Summary
By product, Specialty Care is the largest at 42% of fiscal 2023 revenue, growing 17% a year over 5 years.
Revenue by segment
Fiscal years, as Sanofi reports them in its 10-K filings; fiscal 2023 total 43.1B EUR.
| Segments | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Share |
|---|---|---|---|---|---|---|---|---|
| Biopharma | — | — | — | — | 33.3B EUR | 37.8B EUR | 37.9B EUR | 88% |
| Consumer Healthcare | 4.8B EUR | 4.7B EUR | 4.7B EUR | 4.4B EUR | 4.5B EUR | 5.2B EUR | 5.2B EUR | 12% |
| Pharmaceuticals | 25.2B EUR | 24.7B EUR | 25.7B EUR | 25.7B EUR | — | — | — | — |
| Vaccines | 5.1B EUR | 5.1B EUR | 5.7B EUR | 6.0B EUR | — | — | — | — |
Revenue by product
Fiscal years, as Sanofi reports them in its 10-K filings; fiscal 2023 total 43.1B EUR.
| Products | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Share |
|---|---|---|---|---|---|---|---|
| Specialty Care | 8.3B EUR | 9.2B EUR | — | 12.8B EUR | 16.5B EUR | 18.0B EUR | 42% |
| General Medicines | 16.4B EUR | 16.5B EUR | — | 14.2B EUR | 14.1B EUR | 12.4B EUR | 29% |
| Vaccines | 5.1B EUR | 5.7B EUR | 6.0B EUR | 6.3B EUR | 7.2B EUR | 7.5B EUR | 17% |
| Consumer Healthcare | 4.7B EUR | 4.7B EUR | 4.4B EUR | 4.5B EUR | 5.2B EUR | 5.2B EUR | 12% |
| Non-Core Assets | — | — | 8.3B EUR | — | — | — | — |
| Core Assets | — | — | 5.6B EUR | — | — | — | — |
| Dupixent | — | — | 3.5B EUR | — | — | — | — |
| Rare Diseases | — | — | 3.0B EUR | — | — | — | — |
| Neurology & Immunology | — | — | 2.4B EUR | — | — | — | — |
| Rare Blood Disorders | — | — | 1.2B EUR | — | — | — | — |
| Industrial sales | — | — | 813M EUR | — | — | — | — |
| Oncology | — | — | 798M EUR | — | — | — | — |
Revenue by region
Fiscal years, as Sanofi reports them in its 10-K filings; fiscal 2025 total 43.6B EUR.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| US | — | 11.9B EUR | 11.5B EUR | 12.8B EUR | 13.5B EUR | 14.4B EUR | 17.0B EUR | 17.3B EUR | 20.0B EUR | 22.2B EUR | 51% |
| Other | — | — | — | — | — | — | 12.2B EUR | 11.7B EUR | 12.1B EUR | 12.3B EUR | 28% |
| Europe | — | — | — | — | — | — | 8.5B EUR | 8.8B EUR | 9.0B EUR | 9.2B EUR | 21% |
| Other countries | 12.2B EUR | 13.7B EUR | 13.5B EUR | 14.3B EUR | 13.4B EUR | 13.6B EUR | — | — | — | — | — |
| North America | 13.0B EUR | — | — | — | — | — | — | — | — | — | — |
| Europe (pre-FY2024 reporting) | 8.7B EUR | 9.5B EUR | 9.4B EUR | 9.1B EUR | 9.2B EUR | 9.8B EUR | — | — | — | — | — |
Questions about Sanofi
Where does Sanofi make its money?
In fiscal 2023, by segment: Biopharma 37.9B EUR, Consumer Healthcare 5.2B EUR.
From Sanofi's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.